Safety and Colon-Cleansing Efficacy of a New Residue-Free Formulation of Sodium Phosphate Tablets

Authors: Rex, Douglas K.1; Schwartz, Howard2; Goldstein, Michael3; Popp, John4; Katz, Seymour5; Barish, Charles6; Karlstadt, Robyn G.7; Rose, Martin7; Walker, Kelli7; Lottes, Sandra7; Ettinger, Nancy7; Zhang, Bing8

Source: The American Journal of Gastroenterology, Volume 101, Number 11, November 2006 , pp. 2594-2604(11)

Publisher: Blackwell Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

OBJECTIVE: A residue-free sodium phosphate tablet (RF-NaP) was formulated that lacks microcrystalline cellulose, which can appear as a whitish residue in the colon. A multicenter, randomized, investigator-blinded study was conducted to compare the colon-cleansing efficacy of 40 or 32 tablets of RF-NaP with the marketed 40-tablet NaP treatment regimen.

METHODS: Eight hundred sixteen patients were randomized prior to colonoscopy to receive either 40 tablets (60 g) of NaP or RF-NaP or 32 tablets (48 g) of RF-NaP. Colon cleansing was assessed using a 4-point scale based on retained “colonic contents.” The primary end point was overall colon-cleansing response rate to treatment (score of excellent/good) versus nonresponse (fair/inadequate).

RESULTS: Seven hundred four patients were included in the efficacy analysis. The overall colon-cleansing response rates were comparable among treatment arms (94.5%, 97.0%, and 95.3% for NaP, RF-NaP 40, and RF-NaP 32 tablets, respectively). Ascending colon-cleansing response rates for RF-NaP 40 (95.7%) and 32 tablets (93.6%) were significantly better than for NaP tablets (88.5%, p < 0.03 for both). Patients treated with RF-NaP 32 tablets experienced less pronounced changes in electrolyte levels and fewer adverse events (138/239, 58%) compared with patients receiving NaP (161/238, 68%, p= 0.07) and RF-NaP 40 tablets (156/236, 66%, p= 0.03). The most common adverse events reported were abdominal distention, nausea, abdominal pain, and vomiting.

CONCLUSIONS: Based on the safety, efficacy, and patient preferences, the 32-tablet RF-NaP regimen was superior to the 40-tablet RF-NaP and NaP regimen for colon cleansing prior to colonoscopy.

(Am J Gastroenterol 2006;101:2594-2604)

Document Type: Research article

DOI: 10.1111/j.1572-0241.2006.00776.x

Affiliations: 1: Indiana University Medical Center, Indianapolis, Indiana 2: Miami Research Associates, Miami, Florida 3: Long Island Gastrointestinal Research, Great Neck, New York 4: Columbia Gastroenterology Associates, Columbia, South Carolina 5: Long Island Clinical Research Associates, Great Neck, New York 6: Wake Research Associates, LLC, Raleigh, North Carolina 7: Salix Pharmaceuticals, Inc., Morrisville, North Carolina 8: MacroStat Inc., Hockessin, Delaware

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$50.39 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A